Fundraising FoxPerception Neuroscience
2 known investors
Find your way into Perception Neuroscience
Sign up to see every warm intro you have to Perception Neuroscience
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Perception Neuroscience team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Perception Neuroscience is a clinical-stage biotech developing R-ketamine (PCN-101), a single-isomer glutamatergic modulator being studied as a rapid-acting antidepressant for patients with treatment-resistant depression. The company licenses intellectual property originally discovered at Chiba University and is running a Phase 2a proof-of-concept clinical trial.
Investors · 2
Frequently asked questions
- What does Perception Neuroscience do?
- Perception Neuroscience is a clinical-stage biotech developing R-ketamine (PCN-101), a single-isomer glutamatergic modulator being studied as a rapid-acting antidepressant for patients with treatment-resistant depression. The company licenses intellectual property originally discovered at Chiba University and is running a Phase 2a proof-of-concept clinical trial.
- Who are Perception Neuroscience's investors?
- Perception Neuroscience's investors include Sofinnova Ventures, WPSS Investments.